The strengths of our study are its prospective nature and the inclusion of young patients with adequate renal function, without overweight, obesity, diabetes, neoplasms, autoimmune disease, graft dysfunction or rejection, which minimizes the bias from these factors on the HPG axis and insulin sensitivity. This evidence concerns the gene INS and Obesity.